Abstract: A culture medium named MV06 enabling growth in vitro of both endothelial progenitor and myocardiac progenitor cells, composed of: Iscove's Modified Dubellco's Medium, Fetal calf serum, Horse serum, L-Glutamin (200 mM (100×)) Penicillin (10000 u/mL)/Streptomycin (1000 ?g/mL), Hu-R Bone Morphogenetic Protein 2 (BMP-2), Hu-R Fibroblast Growth Factor 2 (FGF2), and Hu-R Vascular Endothelial Growth Factor (VEGF).

Abstract: A culture medium named MV06 enabling growth in vitro of both endothelial progenitor and myocardiac progenitor cells, composed of: Iscove's Modified Dubellco's Medium, Fetal calf serum, Horse serum, L-Glutamin (200 mM (100×)) Penicillin (10000 u/mL)/Streptomycin (1000 ?g/mL), Hu-R Bone Morphogenetic Protein 2 (BMP-2), Hu-R Fibroblast Growth Factor 2 (FGF2), and Hu-R Vascular Endothelial Growth Factor (VEGF).

Abstract: A cellular cardiomyoplasty process based on the potential capacity of CD34+ cells to regenerate myocardium after acute myocardial infarct (AMI) and on their collection in blood in which the following phases are performed: Phase 1 a G-CSF-mobilization phase of CD-34+ cell is started as soon as the infarct is stabilized and its impact on heart function has been evaluated; Phase 2 a cell collecting phase is undertaken after G-CSF-mobilization; Phase 3 a cell processing phase is performed to select ex-vivo CD34+ cells and expand them in vitro to achieve around a 20-fold increase of the total number of CD34+ cells; Phase 4 a resuspension phase of the amplified-cell product in a final predetermined volume of autologous plasma, and Phase 5 a packaging phase of the cell suspension in a sterile syringue for reinjection to the patient.

Abstract: The invention concerns a cellular cardiomyoplasty process based on the potential capacity of CD34+ cells to regenerate myocardium after acute myocardial infarct (AMI) and on their collection in blood in which the following phases are performed: Phase 1 a G-CSF-mobilization phase of CD-34+ cell is started as soon as the infarct is stabilized and its impact on heart function has been evaluated. Phase 2 a cells collecting phase is undertaken after G-CSF-mobilization, Phase 3 a cells processing phase is performed to select ex-vivo CD34+ cells and expand them in vitro to achieve around a 20-fold increase of the total number of CD34+ cells. Phase 4 a resuspension phase of the amplified-cell product in a final predetermined volume of autologous plasma, and Phase 5 a packaging phase of the cell suspension in a sterile syringe for reinjection to the patient.